Sanofi CEO: The enterprise AI shift will reshape pharma in 2026
· Source: fortune.com
In short
Sanofi CEO Paul Hudson discusses how AI has moved from experimentation to becoming a vital infrastructure component in pharmaceutical operations. The article highlights AI's impact on drug discovery, clinical trial recruitment, and supply chain management, with specific examples including discovering 10 new drug targets in one year and avoiding $300 million in revenue risk through AI-driven supply chain systems. Hudson emphasizes that 2026 will be the tipping point where AI speculation ends and enterprise-scale implementation becomes fundamental to growth.
Read Original Article — Read the full article on the publisher’s site.
In the issue of week 7, 2026: Agentic AI Moves to Mission-Critical in Supply Chain, Driving Measurable Gains
Tags: pharmaceutical, supply-chain, manufacturing, drug-development, forecasting, optimization